View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 13, 2021updated 11 Jul 2022 2:53pm

Ultimovacs reports positive data from Phase I cancer vaccine trial

The tumour destruction levels following UV1 plus pembrolizumab therapy were comparable across both cohorts of the trial.

Ultimovacs has reported positive top-line data from the second cohort of its Phase I clinical trial of universal cancer vaccine candidate, UV1, plus pembrolizumab as a first-line therapy for metastatic malignant melanoma.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

UV1 works against human telomerase (hTERT), which is seen in more than 80% of cancers at all tumour growth stages.

The vaccine candidate directs the immune system to hTERT antigens to guide CD4 helper T cells to the tumour. This approach triggers an immune system cascade and boosts anti-tumour responses.

The second cohort of the ongoing Phase I trial in the US had ten subjects.

Data showed that the vaccine combination met the primary goal of safety and tolerability, demonstrating robust preliminary signs of clinical response.

In six of the ten subjects, the combination treatment offered tumour shrinkage, an objective response rate of 60%.

Furthermore, the tumours shrank to undetectable levels in three of the subjects, indicating a 30% complete response rate.

The levels of tumour destruction in response to therapy with UV1 plus the checkpoint inhibitor, pembrolizumab, were in line with those observed in the first cohort of 20 subjects from the trial.

After 12 months of treatment, a 90% and 85% overall survival (OS) rate was noted in cohort 2 and cohort 1, respectively, signifying elevated and consistent OS rate across both cohorts.

In addition, median progression-free survival (mPFS) was not attained in both cohorts at one year. The company reported this as a positive outcome, showing that the disease status either improved or was stable in a minimum of 50% of the total trial participants.

Ultimovacs chief medical officer Jens Bjørheim said: “The emerging picture is that the UV1-pembrolizumab combination has a strong safety profile and provides consistently high levels of clinical response in advanced melanoma.

“This latest data adds to the accumulating body of evidence demonstrating that UV1 is safe and can mobilise the immune system to play a transformative role in the treatment of solid tumours.”

The top-line two-year follow-up data from the first cohort of the trial is anticipated in the fourth quarter of this year.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena